U.S. Point of Care Lipid Test Market Size Worth USD 553.25 Million by 2034 | CAGR: 5.9%

The U.S. point of care (POC) lipid test market size is expected to reach USD 553.25 million by 2034, according to a new study by Polaris Market Research. The report “U.S. Point of Care Lipid Test Market Size, Share, Trends, Industry Analysis Report By Product (Instruments, Consumables), By Application, By Disease Indication, By End Use– Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

A point of care (POC) lipid test is a diagnostic tool used to measure lipid levels such as total cholesterol, HDL, LDL, and triglycerides, directly at the site of patient care. It provides rapid results from a small blood sample, often within minutes, without needing a central laboratory.

The U.S. healthcare system is increasingly focusing on preventive care to reduce long-term costs and improve patient outcomes. Regular cholesterol screening is a key part of this approach, especially for at-risk groups such as the elderly or those with diabetes. Point of care lipid tests support this preventive model by offering immediate results during routine visits. This eliminates the need for lab processing and encourages more frequent testing. Preventive care is propelling the U.S. POC lipid test market with wellness programs, employer-sponsored health checks, and government-supported initiatives promoting early detection.

Bottom of Form

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/us-point-of-care-lipid-test-market/request-for-sample

Innovation in diagnostic services and technology is rapidly transforming point of care lipid testing in the U.S. Modern lipid testing devices offer better accuracy, faster results, and user-friendly interfaces, making them ideal for various healthcare settings. Bluetooth-enabled meters, smartphone integration, and compact portable analyzers have increased the utility and convenience of POC lipid tests. Companies such as Abbott and Roche are continuously launching improved products tailored to the U.S. These advancements attract both healthcare providers and patients, further accelerating adoption across clinical and nonclinical environments, thereby driving the POC lipid test market growth.

U.S. Point of Care Lipid Test Market Report Highlights

• In 2024, the consumables segment dominated with the largest share due to its recurring demand and widespread use.
• The hypertriglyceridemia segment is expected to experience significant growth during the forecast period, driven by factors such as obesity, high sugar intake, sedentary lifestyles, and poor diet.
• A few key market players are Abbott Laboratories; Callegari Srl; F. Hoffmann-La Roche Ltd.; Menarini Group; MiCoBio; Nova Biomedical; SD Biosensor, Inc.; Sinocare Inc.; and VivaChek Biotech (Hangzhou) Co., Ltd.

Polaris Market Research has segmented the U.S. point of care lipid test market report on the basis of product, application, disease indication, end use, and region:

By Product (Revenue – USD Million, 2020–2034)

• Instruments
• Consumables

By Application (Revenue – USD Million, 2020–2034)

• Hyperlipidemia
• Hypertriglyceridemia
• Tangier Disease
• Hyperlipoproteinemia
• Familial Hypercholesterolemia
• Others

By Disease Indication (Revenue – USD Million, 2020–2034)

• Lipid and Lipoprotein Disorders
• Atherosclerosis
• Liver and Renal Diseases
• Diabetes Mellitus
• Others

By End Use (Revenue – USD Million, 2020–2034)

• Hospitals
• Clinics
• Research and Diagnostic Laboratories
• Others